Cell MedX Corp. (CMXC) Stock

About Cell MedX Corp.

Cell MedX Corp. is a biotechnology firm dedicated to identifying, developing, and marketing both therapeutic and non-therapeutic solutions aimed at individuals suffering from conditions such as diabetes, Parkinson's disease, hypertension, neuropathy, and various kidney-related ailments. The company's offerings include the eBalance Pro System, designed for clinical application by medical professionals, and the eBalance Home System, intended for personal use to promote general well-being and alleviate pain. Both systems are managed by the eBalance Console, a central control unit featuring three distinct pre-programmed microcurrent algorithms: wellness, pain management, and a dual mode. Originally established in 2010 as Sports Asylum, Inc., the company adopted its current name, Cell MedX Corp., in September 2014. Its operations are headquartered in Carson City, Nevada.

Cell MedX Corp. is headquartered in US.

Cell MedX Corp. (CMXC) stock trades at $0.43 with a market capitalization of $126.33M. The stock is valued at a negative price-to-earnings (P/E) ratio of -11.01, reflecting a net loss over the last twelve months, a negative price-to-book of -5.29, reflecting negative shareholders' equity, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.43 and $0.43, and currently trades at or near its 52-week high.

On profitability, Cell MedX Corp. generates a return on equity (ROE) of 60.42%, above the typical market range of roughly 12-15%, return on capital employed of -25.87%.

Official website: www.cellmedx.com